Published in Int J Clin Exp Pathol on January 01, 2008
Effects of inflammatory cytokine IL-27 on the activation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res Ther (2010) 1.02
DNA methylation profiling reveals novel diagnostic biomarkers in renal cell carcinoma. BMC Med (2014) 0.92
IL-27 alleviates the bleomycin-induced pulmonary fibrosis by regulating the Th17 cell differentiation. BMC Pulm Med (2015) 0.79
The association between single nucleotide polymorphism in interleukin-27 gene and recurrent pregnancy loss in Iranian women. Iran J Reprod Med (2015) 0.77
Cigarette Smoke Induction of Interleukin-27/WSX-1 Regulates the Differentiation of Th1 and Th17 Cells in a Smoking Mouse Model of Emphysema. Front Immunol (2016) 0.75
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 46.36
The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell (2006) 33.94
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med (2005) 28.73
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature (2003) 22.89
Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity (2000) 16.03
Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity (2006) 10.53
IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity (2002) 8.19
Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol (2006) 7.89
Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol (2006) 6.82
Understanding the IL-23-IL-17 immune pathway. Trends Immunol (2005) 6.79
Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol (1997) 5.38
Interleukin-6: from basic science to medicine--40 years in immunology. Annu Rev Immunol (2005) 5.27
Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol (2007) 4.90
New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol (2005) 4.53
IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol (2002) 4.33
WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol (2004) 3.55
Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol (2003) 3.07
Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J (1994) 2.83
Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature (2000) 2.51
WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity (2001) 2.49
IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms. Proc Natl Acad Sci U S A (2003) 2.45
A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol (1996) 2.34
Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem (2001) 2.30
The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity. J Immunol (2004) 2.09
IL-27 and IFN-alpha signal via Stat1 and Stat3 and induce T-Bet and IL-12Rbeta2 in naive T cells. J Interferon Cytokine Res (2003) 2.08
Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci U S A (1997) 2.02
Protection from lethal septic peritonitis by neutralizing the biological function of interleukin 27. J Exp Med (2006) 1.78
Disruption of T helper 2-immune responses in Epstein-Barr virus-induced gene 3-deficient mice. Proc Natl Acad Sci U S A (2002) 1.73
IL-27 signaling compromises control of bacterial growth in mycobacteria-infected mice. J Immunol (2004) 1.66
Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to leishmania donovani infection but develop severe liver immunopathology. Am J Pathol (2006) 1.57
Augmentation of effector CD8+ T cell generation with enhanced granzyme B expression by IL-27. J Immunol (2005) 1.50
Positive and negative regulation of the IL-27 receptor during lymphoid cell activation. J Immunol (2005) 1.48
Regulation of IL-27 p28 gene expression in macrophages through MyD88- and interferon-gamma-mediated pathways. J Exp Med (2007) 1.47
A role for IL-27 in early regulation of Th1 differentiation. J Immunol (2005) 1.45
Cloning and characterization of a novel class I cytokine receptor. Biochem Biophys Res Commun (1998) 1.37
Identification of polymorphisms in human interleukin-27 and their association with asthma in a Korean population. J Hum Genet (2007) 1.30
Expression of IL-27 in human Th1-associated granulomatous diseases. J Pathol (2004) 1.25
IL-27 subunits and its receptor (WSX-1) mRNAs are markedly up-regulated in inflammatory cells in the CNS during experimental autoimmune encephalomyelitis. J Neurol Sci (2005) 1.24
Alternatively activated macrophages express the IL-27 receptor alpha chain WSX-1. Immunobiology (2006) 1.23
Exacerbation of experimental allergic asthma by augmented Th2 responses in WSX-1-deficient mice. J Immunol (2005) 1.20
Differential effects of IL-27 on human B cell subsets. J Immunol (2006) 1.18
IL-12 family members: differential kinetics of their TLR4-mediated induction by Salmonella enteritidis and the impact of IL-10 in bone marrow-derived macrophages. Int Immunol (2005) 1.17
Suppression of ongoing adjuvant-induced arthritis by neutralizing the function of the p28 subunit of IL-27. J Immunol (2004) 1.17
Analysis of interleukin-27 (EBI3/p28) expression in Epstein-Barr virus- and human T-cell leukemia virus type 1-associated lymphomas: heterogeneous expression of EBI3 subunit by tumoral cells. Am J Pathol (2005) 1.13
WSX-1: a key role in induction of chronic intestinal nematode infection. J Immunol (2004) 1.08
Induction of IgG2a class switching in B cells by IL-27. J Immunol (2004) 1.07
Suppression of ongoing experimental autoimmune encephalomyelitis by neutralizing the function of the p28 subunit of IL-27. J Immunol (2004) 1.05
The power of combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in infectious diseases. Med Microbiol Immunol (2003) 1.03
No inhibition of IL-27 signaling by soluble gp130. Biochem Biophys Res Commun (2005) 0.98
All in the family: IL-27 suppression of T(H)-17 cells. Nat Immunol (2006) 0.97
Variable expression of Epstein-Barr virus-induced gene 3 during normal B-cell differentiation and among B-cell lymphomas. J Pathol (2006) 0.93
WSX-1 plays a significant role for the initiation of experimental autoimmune uveitis. Int Immunol (2006) 0.90
IFN-gamma-inducing transcription factor, T-bet is upregulated by estrogen in murine splenocytes: role of IL-27 but not IL-12. Mol Immunol (2006) 0.86
Epstein-Barr virus (EBV) infection and expression of the interleukin-12 family member EBV-induced gene 3 (EBI3) in chronic inflammatory bowel disease. J Med Virol (2004) 0.86
Female steroid hormones use signal transducers and activators of transcription protein-mediated pathways to modulate the expression of T-bet in epithelial cells: a mechanism for local immune regulation in the human reproductive tract. Mol Endocrinol (2005) 0.85
Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction. Nat Biotechnol (2011) 1.91
Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. J Immunol (2005) 1.35
Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol (2013) 1.34
Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. J Exp Med (2005) 1.31
S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. Cancer Res (2011) 1.25
Ischemic neurons recruit natural killer cells that accelerate brain infarction. Proc Natl Acad Sci U S A (2014) 1.16
IL-27 enhances the survival of tumor antigen-specific CD8+ T cells and programs them into IL-10-producing, memory precursor-like effector cells. Eur J Immunol (2013) 1.06
Increased Th17 and regulatory T cell responses in EBV-induced gene 3-deficient mice lead to marginally enhanced development of autoimmune encephalomyelitis. J Immunol (2012) 1.01
Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy. Eur J Immunol (2010) 1.00
MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Cancer Lett (2013) 0.99
Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions. PLoS One (2012) 0.99
Cytokine-induced killer T cells kill immature dendritic cells by TCR-independent and perforin-dependent mechanisms. J Leukoc Biol (2006) 0.98
IL-21 receptor expression determines the temporal phases of experimental autoimmune encephalomyelitis. Exp Neurol (2007) 0.98
Perinatal blockade of b7-1 and b7-2 inhibits clonal deletion of highly pathogenic autoreactive T cells. J Exp Med (2002) 0.98
Autoreactive T cells escape clonal deletion in the thymus by a CD24-dependent pathway. J Immunol (2008) 0.95
CD24 on the resident cells of the central nervous system enhances experimental autoimmune encephalomyelitis. J Immunol (2007) 0.94
Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses. PLoS One (2013) 0.94
Targeting activation-induced cytidine deaminase overcomes tumor evasion of immunotherapy by CTLs. J Immunol (2010) 0.87
Overcoming immune evasion in T cell therapy of cancer: lessons from animal models. Curr Mol Med (2008) 0.83
The Yin and Yang aspects of IL-27 in induction of cancer-specific T-cell responses and immunotherapy. Immunotherapy (2015) 0.83
The role of CD200-CD200R in tumor immune evasion. J Theor Biol (2013) 0.81
Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis? Int Immunol (2006) 0.80
The role of IL-27 in the induction of anti-tumor cytotoxic T lymphocyte response. Am J Transl Res (2013) 0.80
CD24 on thymic APCs regulates negative selection of myelin antigen-specific T lymphocytes. Eur J Immunol (2012) 0.79
The role of tumor expression of CD200 in tumor formation, metastasis and susceptibility to T lymphocyte adoptive transfer therapy. Oncoimmunology (2012) 0.78
Research on stress-induced apoptosis of natural killer cells and the alteration of their killing activity in mouse liver. World J Gastroenterol (2013) 0.77
Conformal Nanoencapsulation of Allogeneic T Cells Mitigates Graft-versus-Host Disease and Retains Graft-versus-Leukemia Activity. ACS Nano (2016) 0.76
RNA interference-mediated FANCF silencing sensitizes OVCAR3 ovarian cancer cells to adriamycin through increased adriamycin-induced apoptosis dependent on JNK activation. Oncol Rep (2013) 0.75
Therapeutic effect of anthracene-based anticancer agent ethonafide in an animal model of multiple sclerosis. J Immunol (2007) 0.75
On the role of unmutated antigens in tumor rejection in mice with unperturbed T-cell repertoires. Cancer Res (2003) 0.75